Recurrent Nasopharyngeal Carcinoma and the Role of Surgery

Anirudh Saraswathula¹ Nyall R. London Jr.¹,²

¹ Department of Otolaryngology–Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
² Sinonasal and Skull Base Tumor Program, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States

Abstract

Recurrent nasopharyngeal carcinoma (rNPC) presents unique challenges as reirradiation comes with significant treatment-related morbidity in swallowing, middle ear function, and large-vessel integrity. Advances in endoscopic technology have made surgery for rNPC an increasingly viable option for select patients and may play a role in providing a better quality of life to patients with this challenging disease. In carefully selected patients, endoscopic and open surgical approaches may provide comparable disease control while mitigating long-term treatment-related morbidity.

Introduction

Nasopharyngeal carcinoma (NPC) is an uncommon malignancy endemic to Southeast Asia, and its recurrent form (rNPC) presents unique treatment challenges. Although reirradiation for rNPC has traditionally been the mainstay of treatment, it comes with significant treatment-related morbidity in swallowing, middle ear function, and large-vessel integrity. In carefully selected patients, endoscopic and open surgical approaches may provide comparable disease control while mitigating long-term treatment-related morbidity.

Case Presentation

A 65-year-old man presented 1 year after receiving definitive 70 Gy intensity-modulated radiation therapy (IMRT) in 35 fractions for a cT1N0 left NPC. A posttreatment positron emission tomography-computed tomography (PET-CT) at that time showed no residual fluorodeoxyglucose-avidity. The referring physician noticed a raised lesion in the left nasopharynx, which biopsy revealed to be poorly differentiated human papillomavirus+ Epstein–Barr virus squamous cell carcinoma. PET-CT and magnetic resonance imaging were performed (Fig. 1), the patient was seen by the multidisciplinary team, and presented at tumor board who recommended surgical resection. An expanded endonasal approach was performed for tumor extirpation.

Discussion

There are several treatment options for locally rNPC, including: reirradiation, proton beam therapy, endoscopic nasopharyngectomy, and open nasopharyngectomy.¹ For metastatic disease, systemic therapy is the mainstay. In the absence of metastatic disease, the 2019 International Consensus Statements on Allergy and Rhinology suggests that endoscopic nasopharyngectomy is a reasonable approach for rT1 and rT2 NPC.² A 2023 meta-analysis of salvage treatments for locally recurrent NPC showed in a pooled analysis that endoscopic nasopharyngectomy had improved 5-year survival to IMRT.
(61% vs. 41%). While selection bias is certainly a factor, this presented endoscopic surgery as a viable option for good candidates and with a better long-term safety profile (avoiding reirradiation to prevent swallowing dysfunction from radiation fibrosis, impaired middle ear ventilation, or carotid blowout syndrome).1 The 2-year overall survival for rNPC patients is low, but comparable when examining endoscopic versus open surgery (rT2 [77% vs. 63%], rT3 [67% vs. 53%], rT4 [35% vs. 35%]). Complication rates are lower with endoscopic surgery, however.3 Treatment-associated mortality from IMRT was 32% compared to 3% for either open or endoscopic surgery.1

While several approaches to endoscopic nasopharyngectomy have been described, the Castelnuovo schema4 is widely used. Type 1 and type 2 nasopharyngectomy are indicated for smaller nasopharyngeal tumors with dissection extending from the level of the superior nasopharynx down to the level of C1. The Eustachian tube is preserved. Type 3 nasopharyngectomy is the most extensive and is indicated for more extensive and lateralized tumors. In addition to the exposure for type 2 (which involves bilateral sphenoidectomies), it also requires a medial maxillectomy and a transpterygoid dissection with mobilization of the pterygopalatine fossa contents, extending as far laterally as the parapharyngeal carotid artery. In this approach, the cartilaginous Eustachian tube is sacrificed. In this case presentation, the patient underwent a type 3 Castelnuovo nasopharyngectomy and the defect was reconstructed with a Hadad–Bassagasteguy nasoseptal flap.5

Alternately, open approaches have also been described, particularly for larger tumors. The maxillary swing is the most common open approach to the nasopharynx,6 and if the carotid artery is involved, either a balloon occlusion test with carotid sacrifice or extracranial/intracranial vascular bypass from the internal carotid artery to the middle cerebral artery can be considered in select patients.7

**Conclusion**

With the advantage of avoiding long-term morbidity and mortality from radiation complications, advances in endoscopic technology have made surgery for rNPC an increasingly viable option for select patients. The treatment of locally rNPC continues to evolve rapidly, and looking forward, surgery may increasingly play a role to provide a better quality of life to patients with this challenging disease entity.

**Informed Consent**

Informed consent was obtained from the patient for images and video presented in this article.

**Funding**

A.S. is supported by the National Institute on Deafness and Other Communication Disorders training grant T32DC000027. This research was supported (in part) by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute.

**Conflict of Interest**

Dr. London reported receiving grants from Merck Sharp & Dohme and holding stock in Navigen Pharmaceuticals

**References**

6 London NR Jr, Chan JYW, Carrau RL. Transpalatal approaches to the skull base and reconstruction: indications, technique, and associated morbidity. Semin Plast Surg 2020;34(02):99–105